Jounce Therapeutics (JNCE) Short Interest Ratio & Short Volume → The AI Bottleneck No One is Talking About (From The Bull Report) (Ad) Free JNCE Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Short InterestStock Analysis Jounce Therapeutics Short Interest DataCurrent Short Volume2,020,000 sharesPrevious Short Volume2,280,000 sharesChange Vs. Previous Month-11.40%Dollar Volume Sold Short$3.88 millionShort Interest Ratio / Days to Cover0.8Last Record DateApril 15, 2023Outstanding Shares52,630,000 sharesFloat Size43,940,000 sharesShort Percent of Float4.60%Today's Trading Volume11,600,600 sharesAverage Trading Volume2,457,142 sharesToday's Volume Vs. Average472% Short Selling Jounce Therapeutics ? Sign up to receive the latest short interest report for Jounce Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatJNCE Short Interest Over TimeJNCE Days to Cover Over TimeJNCE Percentage of Float Shorted Over Time Ad Behind the MarketsThe only AI company you should be looking atThis is the ONLY AI company you should be watching right now. No. It's not Nvidia, Intel, or Microsoft... It's a tiny biotech using proprietary AI to assist in new drug discovery at a rate 100,000 times faster than a human. This new drug discovery technique will change the market. And that's why they received a $50 million investment from an AI powerhouse.Get the stock ticker here >>> Jounce Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/15/20232,020,000 shares $3.88 million -11.4%4.6%0.8 $1.92 3/31/20232,280,000 shares $4.22 million -28.3%5.2%0.9 $1.85 3/15/20233,180,000 shares $4.74 million -23.7%7.2%1.1 $1.49 2/28/20234,170,000 shares $4.67 million +202.2%9.6%1.7 $1.12 2/15/20231,380,000 shares $1.55 million +3.0%3.2%0.6 $1.12 1/31/20231,340,000 shares $1.57 million -15.2%3.4%0.9 $1.17 Get the Latest News and Ratings for JNCE and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Jounce Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 1/15/20231,580,000 shares $1.94 million -46.3%4.0%1 $1.23 12/30/20222,940,000 shares $3.26 million +208.6%7.4%2 $1.11 12/15/2022952,600 shares $677,108.08 -15.0%2.4%1.8 $0.71 11/30/20221,120,000 shares $985,600.00 -17.0%2.8%3.3 $0.88 11/15/20221,350,000 shares $1.36 million -8.2%3.4%4.3 $1.01 10/31/20221,470,000 shares $3.20 million -5.2%3.9%5.5 $2.18 10/15/20221,550,000 shares $3.05 million -22.5%4.1%5.3 $1.97 9/30/20222,000,000 shares $4.68 million +1.0%5.9%7.8 $2.34 9/15/20221,980,000 shares $6.16 million -3.4%5.9%7.6 $3.11 8/31/20222,050,000 shares $7.50 million -5.5%6.1%7.3 $3.66 8/15/20222,170,000 shares $10.57 million +1.9%6.4%7.5 $4.87 7/31/20222,130,000 shares $6.54 million -4.5%7.0%6.8 $3.07 7/15/20222,230,000 shares $7.63 million +8.3%7.4%7 $3.42 6/30/20222,060,000 shares $6.24 million +0.5%6.8%6 $3.03 6/15/20222,050,000 shares $6.01 million +5.7%6.8%5.2 $2.93 5/31/20221,940,000 shares $7.51 million +19.8%6.4%5.1 $3.87 5/15/20221,620,000 shares $7.06 million +4.5%5.3%3.9 $4.36 4/30/20221,550,000 shares $8.22 million +4.7%5.4%3.8 $5.30 4/15/20221,480,000 shares $10.03 million +1.4%4.6%3.7 $6.78 3/31/20221,460,000 shares $9.91 million -0.7%4.6%3.9 $6.79 3/15/20221,470,000 shares $10.13 million +1.4%4.6%4.4 $6.89 2/28/20221,450,000 shares $10.82 million +31.8%4.6%4.4 $7.46 2/15/20221,100,000 shares $8.84 million -6.8%3.5%3.4 $8.04 1/31/20221,180,000 shares $8.83 million +7.3%3.6%3 $7.48 1/15/20221,100,000 shares $6.91 million -0.9%3.3%2.7 $6.28 12/31/20211,110,000 shares $9.27 million +6.7%3.3%2.7 $8.35 12/15/20211,040,000 shares $7.78 million +20.5%3.1%2.4 $7.48 11/30/2021862,800 shares $6.62 million -2.8%2.6%1.7 $7.67 11/15/2021887,500 shares $7.68 million -38.4%2.7%1.8 $8.65 10/29/20211,440,000 shares $12.64 million -8.3%4.4%3.2 $8.78 10/15/20211,570,000 shares $13.36 million -3.1%5.0%3.9 $8.51 9/30/20211,620,000 shares $12.04 million +27.6%5.2%4.1 $7.43 9/15/20211,270,000 shares $9.86 million -27.4%4.1%2.7 $7.76 8/31/20211,750,000 shares $10.89 million -12.9%5.6%3.7 $6.228,788% Return Predicted For THIS Crypto (already up 40% in 6 months) (Ad)THIS cryptocurrency has gained 40% in 6 months. A crypto millionaire who has researched the space for a decade says it will go up 8,788% in 5 years. The name of this cryptocurrency is revealed right here: Click to get the name of the cryptocurrency JNCE Short Interest - Frequently Asked Questions What is Jounce Therapeutics' current short interest? Short interest is the volume of Jounce Therapeutics shares that have been sold short but have not yet been covered or closed out. As of April 15th, investors have sold 2,020,000 shares of JNCE short. 4.60% of Jounce Therapeutics' shares are currently sold short. Learn More on Jounce Therapeutics' current short interest. What is a good short interest ratio for Jounce Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. JNCE shares currently have a short interest ratio of 1.0. Learn More on Jounce Therapeutics's short interest ratio. What is a good short interest percentage for Jounce Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 4.60% of Jounce Therapeutics' floating shares are currently sold short. Is Jounce Therapeutics' short interest increasing or decreasing? Jounce Therapeutics saw a decline in short interest in April. As of April 15th, there was short interest totaling 2,020,000 shares, a decline of 11.4% from the previous total of 2,280,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Jounce Therapeutics' float size? Jounce Therapeutics currently has issued a total of 52,630,000 shares. Some of Jounce Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Jounce Therapeutics currently has a public float of 43,940,000 shares. How does Jounce Therapeutics' short interest compare to its competitors? 4.60% of Jounce Therapeutics' shares are currently sold short. Here is how the short interest of companies in the sector of "medical" compare to Jounce Therapeutics: Cardiol Therapeutics Inc. (0.58%), Athira Pharma, Inc. (2.22%), Protalix BioTherapeutics, Inc. (7.70%), aTyr Pharma, Inc. (0.18%), Outlook Therapeutics, Inc. (7.89%), AlloVir, Inc. (5.16%), Genenta Science S.p.A. (0.02%), Instil Bio, Inc. (0.33%), Passage Bio, Inc. (1.51%), BioAtla, Inc. (10.66%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($4.69 billion), Occidental Petroleum Co. ($3.22 billion), Coinbase Global, Inc. ($2.54 billion), T. Rowe Price Group, Inc. ($2.33 billion), Paramount Global ($2.10 billion), Verisk Analytics, Inc. ($2.03 billion), Etsy, Inc. ($1.67 billion), Old Dominion Freight Line, Inc. ($1.62 billion), CarMax, Inc. ($1.60 billion), and Extra Space Storage Inc. ($1.60 billion). View all of the most shorted stocks. What does it mean to sell short Jounce Therapeutics stock? Short selling JNCE is an investing strategy that aims to generate trading profit from Jounce Therapeutics as its price is falling. JNCE shares are trading down $0.05 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Jounce Therapeutics? A short squeeze for Jounce Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of JNCE, which in turn drives the price of the stock up even further. How often is Jounce Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including JNCE, twice per month. The most recent reporting period available is April, 15 2023. More Short Interest Resources from MarketBeat Related Companies: CRDL Short Squeeze ATHA Short Squeeze PLX Short Squeeze LIFE Short Squeeze OTLK Short Squeeze ALVR Short Squeeze GNTA Short Squeeze TIL Short Squeeze PASG Short Squeeze BCAB Short Squeeze Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:JNCE) was last updated on 3/19/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial Metals8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)Paradigm PressAltcoin FRENZY Alert…Crypto 101 MediaThe AI Bottleneck No One is Talking AboutThe Bull ReportMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyThe world’s greatest investmentPorter & Company